Skip to main content

Table 3 Efficacy endpoints at week 16 by prior TNFi therapy status

From: Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

Endpoints TNFi-naive TNFi-IR
Secukinumab 150 mg (N = 85) Secukinumab 150 mg no load (N = 85) Placebo (N = 83) Secukinumab 150 mg (N = 31) Secukinumab 150 mg no load (N = 32) Placebo (N = 34)
ASAS20, % 60.0 62.4 49.4 58.1 59.4 41.2
ASAS40, % 40.0 38.8 30.1 35.5 28.1 23.5
hsCRP (post-baseline/baseline ratio), LS mean ± SE 0.51 ± 1.09* 0.55 ± 1.09* 1.03 ± 1.10 0.76 ± 1.17 0.76 ± 1.17 1.24 ± 1.17
ASAS 5/6, % 37.6 45.9 30.1 35.5 34.4 26.5
BASDAI, LS mean change from baseline ± SE − 2.54 ± 0.23 − 2.65 ± 0.23 − 2.00 ± 0.23 − 2.08 ± 0.42 − 2.42 ± 0.42 − 1.57 ± 0.40
SF-36 PCS, LS mean change from baseline ± SE 6.74 ± 0.80 7.69 ± 0.81 5.24 ± 0.82 5.21 ± 1.28 6.54 ± 1.26 3.95 ± 1.21
ASQoL, LS mean change from baseline ± SE − 4.49 ± 0.50 − 5.13 ± 0.50§ − 3.26 ± 0.51 − 2.72 ± 0.80 − 3.49 ± 0.79 − 2.52 ± 0.76
  1. ASAS Assessment of Spondyloarthritis International Society, ASQoL ankylosing spondylitis quality of life, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, hsCRP high-sensitivity C-reactive protein, IR inadequate responder, LS least squares, N number of patients randomized, SE standard error, SF-36 PCS short form-36 physical component summary, TNFi tumor necrosis factor-alpha inhibitors
  2. *P < 0.0001; §P < 0.01; P < 0.05 versus placebo (P values are unadjusted). Non-responder imputation (binary variables) and mixed-effect model repeated measures (continuous variables) analyses presented